| Autor: |
Razumova IY; Krasnov Research Institute of Eye Diseases, Moscow, Russia., Godzenko AA; Russian Medical Academy of Continuous Professional Education, Moscow, Russia. |
| Jazyk: |
ruština |
| Zdroj: |
Vestnik oftalmologii [Vestn Oftalmol] 2022; Vol. 138 (6), pp. 108-114. |
| DOI: |
10.17116/oftalma2022138061108 |
| Abstrakt: |
This review is devoted to the potential application of genetically engineered biological drugs of different classes in the treatment of main forms of uveitis and other types of non-infectious ocular inflammation in immunoinflammatory rheumatic diseases. The article presents the results of studies demonstrating the influence of interleukin-17 inhibitor secukinumab on the course of uveitis in spondylarthritis, shows the possibilities of treating uveitis in juvenile idiopathic arthritis with inhibitors of interleukin-6, co-stimulation of T-lymphocytes. Inhibition of interleukin-1 is considered an effective method of influencing the ocular inflammation in monogenic autoinflammatory syndromes and Behcet's disease. Rituximab is considered as an option for immunosuppressive therapy of non-infectious uveitis and scleritis. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
